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ABSTRACT 
In head and neck squamous cell carcinoma (HNSCC), the human epidermal growth 
factor receptor 1 (EGFR) is the dominant signaling molecule among all members of the 
family. So far, cetuximab is the only approved anti-EGFR mAb used for the treatment of 
HNSCC, but despite the benefits of adding it to standard treatment regimens, attempts 
to define a predictive biomarker to stratify patients for cetuximab treatment have been 
unsuccessful. We hypothesized that imaging with EGFR-specific radioligands may 
facilitate non-invasive measurement of EGFR expression across the entire tumor 
burden and also allow for dynamic monitoring of cetuximab-mediated changes in 
receptor expression. Methods: EGFR-specific Affibody molecule (ZEGFR:03115) was 
radiolabeled with zirconium-89 (89Zr) and fluorine-18 (18F). The radioligands were 
characterized in vitro and in mice bearing subcutaneous tumors with varying levels of 
EGFR expression. The protein dose for imaging studies was assessed by injecting 89Zr-
DFO-ZEGFR:03115 (2.4-3.6 MBq, 2 µg) either together with or 30 mins after increasing 
amounts of unlabeled ZEGFR:03115 (1, 5, 10, 15 and 20 µg). PET images were acquired at 
3, 24 and 48 h post-injection and the image quantification data were correlated with the 
biodistribution results. The EGFR expression and biodistribution of the tracer were 
assessed ex vivo by immunohistochemistry, Western blot and autoradiography. To 
downregulate the EGFR level, treatment with cetuximab was performed and 18F-AlF-
NOTA-ZEGFR:03115 (12 µg, 1.5-2 MBq/mouse) used to monitor receptor changes. 
Results: In vivo studies demonstrated that co-injecting 10 µg of non-labeled molecules 
with 89Zr-DFO-ZEGFR:03115 allows for clear tumor visualization 3 h post-injection. The 
radioconjugate tumor accumulation was EGFR-specific and PET imaging data showed 
a clear differentiation between xenografts with varying EGFR expression levels. A 
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strong correlation was observed between PET analysis, ex vivo estimates of tracer 
concentration and receptor expression in tumor tissues. Additionally, 18F-AlF-NOTA-
ZEGFR:03115 could measure receptor downregulation in response to EGFR inhibition.  
Conclusion: ZEGFR03115-based radioconjugates can assess different levels of EGFR 
level in vivo and measure receptor expression changes in response to cetuximab, 
indicating a potential for assessment of adequate treatment dosing with anti-EGFR 
antibodies.  
 
Key Words: Affibody molecules; EGFR, zirconium-89, fluorine-18, cancer imaging 
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INTRODUCTION 
Globally, head and neck squamous cell cancer (HNSCC) is the sixth most common 
cancer; its treatment consists of surgery and/or radiotherapy, with or without concurrent 
chemotherapy or targeted therapy (1). Disappointingly, patient survival has not 
markedly improved in recent decades and approximately 50% of patients with locally 
advanced disease will develop recurrence or metastases within 2 years. Such 
differences in outcome are largely driven by inter- and intra-patient heterogeneity in 
disease biology (2).  
Of note, in HNSCC the human epidermal growth factor receptor 1 (EGFR) is the 
dominant member of the HER family (3). EGFR mRNA and receptor expression were 
found to be elevated in 92% and 38-47% of cases, respectively (3,4). Furthermore, this 
aberrant receptor expression and activity was positively correlated with poor patient 
prognosis and resistance to radiation therapy (5). These findings led to the development 
and widespread implementation of specific anti-EGFR inhibitors, including monoclonal 
antibodies (mAbs) targeting the extracellular domain of EGFR (e.g. cetuximab, 
panitumumab, zalutumumab) and small molecule tyrosine kinase inhibitors that target 
the intracellular domain (e.g. gefinitib, erlotinib) (6). So far, cetuximab is the only anti-
EGFR therapy agent approved for the treatment of HNSCC. However, despite the 
clearly documented clinical benefits of cetuximab, attempts to define a predictive 
biomarker to stratify patients for treatment with the antibody have been unsuccessful. 
Remarkably, measuring levels of EGFR protein expression or receptor activation (e.g. 
the presence of activating gene mutations) have not demonstrated any predictive value 
benefit to cetuximab treatment in HNSCC. In the context of radical, curative 
radiotherapy/chemoradiotherapy, dichotomising EGFR expression into low vs high 
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levels (defined as < or >50% positive cells in the trial with radiotherapy and < or >80% 
positive cells in the RTOG0522 study with chemoradiotherapy), did not predict benefit 
from the addition of cetuximab (2,7,8). Similarly, in the EXTREME trial of first-line use of 
platin/5-FU/cetuximab in relapsed/metastatic disease, outcomes were essentially 
identical for patients with < or >40% EGFR-positive tumor cells (9). As a consequence, 
at present the clinical use of cetuximab is not based on the measurement of intra-
tumoral EGFR expression or, indeed, any other biomarker. Against this background, it is 
important to consider the context in which EGFR has been assessed in previous clinical 
studies, in order to understand the limitations of the methodologies employed. At this 
moment, no serum biomarker has been identified that could consistently classify an 
EGFR+ve subgroup of patients for targeted therapies, so in most clinical trials, EGFR 
expression has been measured via immunohistochemical staining before the initiation of 
therapy at a single, static time point, and on a relatively small tissue sample (10). For 
patients with relapsed/metastatic disease, the assessment may have been performed 
on archival specimens and furthermore, the reported immunohistochemistry data are 
subject to variability in the sensitivity and specificity of reagents, the use of different 
staining protocols and concerns relating to the tissue sample that could have provided 
an unrepresentative view of heterogeneous receptor expression. Therefore, we 
hypothesized that incorporating imaging with EGFR-specific radioligands into routine 
clinical practice may not only facilitate a non-invasive, real-time measurement of EGFR 
expression across the patient’s entire tumor burden, but also allow for dynamic 
monitoring of cetuximab-mediated receptor downregulation providing a marker for 
adequate treatment dosing.  
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To date, the use of EGFR-specific molecular imaging for HNSCC patients has 
been limited to radiolabeled mAbs. And even though, they have demonstrated high 
uptake in EGFR+ve tumors, their large molecular size (~ 150 kDa) and consequential 
slow hepatobiliary clearance (e.g. cetuximab half-life in humans is about 95 h) resulted 
in  poor contrast between tumor and normal tissues on images acquired at earlier time 
points (11,12). Accordingly, using smaller molecules, such as mAb fragments (e.g. 
F(ab’)2, Fab’), nanobodies (~15 kDa), or Affibody scaffolds (~7 kDa) that are 
characterized by rapid tumor penetration and fast blood clearance, could facilitate high-
contrast imaging as early as a few hours post-injection (13). Indeed, these favourable 
pharmacokinetics have been demonstrated by PET imaging of EGFR-expressing 
xenografts using EGFR specific Affibody molecules conjugated to several radioisotopes 
such as, fluorine-18 (14,15), zirconium-89 (16,17) and carbon-11 (18). Of note, a study 
by Garousi et al. recently showed greater tumor-to-blood ratios 3 h post-administration 
of 89Zr-DFO-ZEGFR:2377 in comparison to 48 h post-injection of 89Zr-DFO-cetuximab, 
highlighting the advantage of imaging with smaller molecules (19). 
Herein, we report the use of a radiolabeled Affibody molecule (ZEGFR:03115) to non-
invasively measures differences in EGFR expression, both in vitro and in subcutaneous 
HNSCC xenograft models. A 89Zr-labeled conjugate was used to assess tumor-to-organ 
ratios at different time points and a 18F-labeled analogue to measure the response to 
cetuximab treatment in vivo. These data support the hypothesis that a targeted-PET 
agent can quantify EGFR expression level and may represent a powerful missing tool 
that will facilitate informed image-guided anti-EGFR therapeutic strategies in the clinic.  
  
by Inst of Cancer Rsrch Lib on November 2, 2018. For personal use only. jnm.snmjournals.org Downloaded from 
8 
 
MATERIALS AND METHODS 
Cell Lines 
Human head and neck cancer cell line HN5 (EGFR++++) was provided by 
Professor Kevin Harrington (The Institute of Cancer Research, London, UK), CAL27 
(EGFR+++), Detroit562 (EGFR++) cell lines and the human breast adenocarcinoma cell 
line MCF7 (EGFR+) were purchased from the American Type Culture Collection (ATCC, 
USA). Cells were cultured in DMEM (Gibco, Life Technologies, UK) supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Gibco, Life Technologies, UK) and 
grown as monolayers at 37°C in a humidified atmosphere containing 5% CO2.  
 
Preparation of ZEGFR:03115-DyLight633, 89Zr-DFO- and 18F-AlF-NOTA Affibody 
Conjugates  
The conjugation of DyLight633, DFO-maleimide and maleimidoethylmonoamide 
NOTA to the Affibody molecules, the consequent 89Zr and 18F-AlF radiolabeling 
procedures are described in the Supplemental Data. 
 
Flow Cytometry Analysis of EGFR Expression 
To assess the EGFR expression in the HN5, CAL27, Detroit562, and MCF7, cell 
lines, samples were incubated for 1 hour at 4°C with either a fluorescein isothiocyanate 
(FITC)-conjugated EGFR-specific antibody (20 nM) (Santa Cruz Biotechnology, TX). 
Afterwards, the cells were washed in PBS and analyzed on the BD™ LSRII flow 
cytometer (Becton Dickinson, NJ). The results were analyzed using FlowJo v10 
(FlowJo, LLC).  
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Confocal Microscopy 
The binding specificity of the Affibody molecule to EGFR was assessed by 
incubating HN5 cells with ZEGFR:03115-Dylight633 (1 µM) for 1 h at 37°C with and without 
pre-incubation with 100-fold excess of the ZEGFR:03115. To study the internalization of the 
conjugate HN5 cells were incubated with ZEGFR:03115-Dylight633 (1 µM) for 1 h at 37°C, 
washed with PBS, and confocal images were acquired at 3, 8 and 24 h post-incubation. 
All cells were counterstained with Hoechst®33342 (nuclear stain; Thermo Fisher 
Scientific, UK) and Lysotracker™ Green DND-26 (lysosome stain; Thermo Fisher 
Scientific, UK) 1 h before capturing the images using the Zeiss LSM700 confocal 
microscope (Carl Zeiss Inc, Germany). Images (8 bit, 1024 x 1024) were analyzed using 
the Zen2009 software (Zeiss, Germany).  
 
Immunoblotting  
Western blotting was carried out as previously described in the literature (20). 
Briefly, the proteins were immunoblotted with primary antibodies against EGFR, p-
EGFR (Tyr1068), AKT (Protein kinase B), p-AKT (S473), β-Actin or GAPDH (all from 
Cell Signaling Technology, UK,) overnight at 4°C. On the following day, membranes 
were rinsed and incubated with horseradish peroxidase-conjugated secondary 
antibodies (Cell Signaling Technology, UK) for 1 h at RT. The immunoblots were 
visualized following the addition of SuperSignal™ West Pico PLUS Chemiluminescent 
Substrate (Thermo Fisher Scientific, UK) and imaged with a ChemiDocTM XRS+ System 
(Bio-Rad, UK). The densitometry was performed using ImageJ (NIH, WA). 
 
In vitro Binding Affinity and Specificity  
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The disassociation constants (Kd) of 89Zr- and 18F-AlF-based ZEGFR:03115 
conjugates were assessed by a saturation binding assay. The CAL27 cells were 
incubated with increasing concentrations of radiolabeled ZEGFR:03115 (0.1 – 50 nM) for 2 h 
at 4°C. Non-specific binding was determined by adding 100-fold excess of unlabeled 
ZEGFR:03115. Cell-bound radioactivity was determined using the 2480WIZARD2 Automatic 
Gamma Counter (PerkinElmer, UK). To estimate the Kd, the data were plotted as the 
amount of bound (nM) vs. ligand (nM). The specific binding was measured by 
subtracting the fraction of the non-specific from the total binding, and fitted using a 
nonlinear regression curve, one-site specific receptor-binding model using GraphPad 
Prism v7.0 Software (San Diego, CA).  
To evaluate the binding specificity of ZEGFR:03115, HN5, CAL27, Detroit562 and MCF7 
cells were incubated with either 89Zr-DFO-ZEGFR:03115 or 18F-AlF-NOTA-ZEGFR:03115  (20 
nM) for 1 h at 4°C. To some of the cells, a 100-fold excess of either cetuximab (Merck, 
Global, Germany), natural EGF ligand (Thermo Fisher Scientific, UK) or unlabeled 
ZEGFR:03115 were added. Afterwards, cells were rinsed, trypsinized and the radioactivity 
was measured using a -counter. Each experiment was normalized to the maximum 
cell-associated radioactivity and presented as the mean of n = 3 independent 
experiments (performed in triplicate) ± SEM.  
 
Biodistribution 
All experiments were performed in compliance with licenses issued under the UK 
Animals (Scientific Procedures) Act 1986. Studies were compliant with the United 
Kingdom National Cancer Research Institute Guidelines for Animal Welfare in Cancer 
Research (21). Female NU(NCr)-Foxn1nu mice were purchased from Charles River 
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Laboratories, UK. To generate tumor xenografts, CAL27 (4x106), Detroit562 (6x106) or 
MCF7 (6.5x106) cells were inoculated in BD Matrigel™ Matrix subcutaneously into the 
shoulder of the mouse. For the MCF7 xenograft model, a 17β-estradiol pellet/mouse 
(0.72 mg, 90-day release) was implanted 48 h before cell inoculation. The tumors were 
allowed to grow until reaching an approximate volume of 100 mm3.  
Dose-dependent 89Zr-DFO-ZEGFR:03115 uptake was assessed by injecting the 89Zr-
DFO- ZEGFR:03115 into the tail vein (2 µg) either together or 30 mins after increasing 
amounts of unlabeled Affibody molecule (1, 5, 10, 15 and 20 µg). 89Zr-ZTaq (3-3.1 MBq, 
2µg) was used as a negative control. Animals were sacrificed at 3, 24 and 48 h post-
injection. Blood was collected and the major organs were excised, weighed and their 
associated radioactivity was measured, using a -counter. Unless otherwise stated, the 
results for each tissue sample were calculated as percentage of the injected dose per 
gram of tissue (%ID/g) (n ≥ 3 mice ± SD). 
 
Autoradiography  
Dissected tumors were embedded in an optimal-cutting-temperature compound 
(Tissue-Tek, USA) and immediately snap frozen on dry ice. The specimens were 
sectioned to a thickness of 6 µm using a cytomicrotome (Thermo Fisher Scientific, UK) 
and mounted on slides. The slides were exposed to a photostimulable phosphor plate 
for 24 h and read using a Typhoon7000 phosphorimager (GE Healthcare Life Sciences, 
UK). The recorded images were analyzed using ImageQuant TL Version 8.1 (GE 
Healthcare Life Sciences, UK). 
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Immunohistochemistry 
Tumors were fixed in formalin and paraffin-embedded to be sectioned and further 
processed (Breast Cancer Now Histopathology Core Facility, London). Multiple sections 
were taken at regular intervals across each tumor, stained with H&E (Leica, Germany) 
and an anti-EGFR mAb (Dako pharmDxTM, UK) according to the manufacturer’s 
protocol and imaged with the NanoZoomer-XR (Hamamatsu Photonics, Japan). 
 
PET Imaging  
Mice were anaesthetized using isoflurane (1.5%–2% v/v in O2) before imaging. 
Using an Albira PET/SPECT/CT preclinical imaging system (Bruker, UK), whole body 
15 min (89Zr) or 10 min (18F) static images were acquired with an energy window of 358 
to 664 keV, followed by CT acquisition. PET data were reconstructed using an MLEM 
algorithm (12 iterations), scatter and attenuation corrections were applied using their 
respective CTs. High resolution CT scans were performed with the X-ray tube set-up at 
a voltage of 45 kV, current of 400 µA, 250 projections (1 sec per projection) and a voxel 
size of 0.5×0.5×0.5 mm3. The CT images were reconstructed using a filtered back 
projection algorithm. The PMOD software package (PMOD Technologies Ltd, CH) was 
used to analyze the images. The tumor volume was selected by first drawing volumes of 
interest around the tumor and selecting a 50% maximum pixel isocontour. The mean 
counts were extracted and converted into %ID/g using a calibration factor 
(MBq/g/counts) calculated by scanning a source (89Zr or 18F) of known activity and 
volume. 
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Cetuximab Treatment 
Cetuximab treatment studies were conducted using HN5 xenografts, as this 
model is particularly sensitive to cetuximab treatment (22). Mice were randomized into 
either control (n = 6) or treatment (n = 7) groups and treated with a vehicle or 
cetuximab, respectively. The control mice were injected with 18F-AlF-NOTA-ZEGFR:03115 
(12 µg, 1.5-2 MBq/mouse), imaged 1 h post-conjugate administration, and sacrificed for 
biodistribution study. Mice from the treatment group underwent cetuximab treatment 
(600 µg bolus injection every 3 days for a total of 4 doses delivered via intraperitoneal 
injection). Allowing 13 days for post-treatment clearance of the mAb, subsequent PET 
images were acquired with 18F-AlF-NOTA-ZEGFR:03115 (12 µg, 1.5-2 MBq/mouse). In 
addition, to demonstrate a lack of competition between the Affibody and remaining 
cetuximab in the blood circulation, an extra group of mice (n = 3) was co-injected with 
cetuximab (3.75 µg, 26 pmol) an amount which was estimated to still be present in the 
blood 13 days after completion of treatment, considering a mAb biological half-life of 40 
h. Densitometric analysis of the tumor tissue lysates was performed using ImageJ (NIH, 
USA). Data are presented as means + SEM (blots n = 2).  
 
Statistical Analysis 
Statistical analyses were performed using Prism software (GraphPad Software 
v7.0).  
Significance was determined using unpaired two-tailed Student’s t test with Welch’s 
correction. In order to determine statistical significance between uptakes in the different 
xenograft models, a two-way ANOVA with Tukey correction was used. Correlation 
analysis was performed using Spearman’s rank correlation, with linear regression, 95% 
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confidence intervals. Statistically significant differences between groups were assumed 
if P ≤ 0.05. No data were excluded from the analysis. 
 
RESULTS 
ZEGFR:03115 Targeting Properties 
Initially, EGFR expression was determined in the selected cancer cell lines by 
Western blot and flow cytometry. The Western blotting results revealed varying levels of 
EGFR expression, from high, HN5 (EGFR++++); through medium, CAL27 (EGFR+++); 
to low, Detroit562 (EGFR++) and negligible in MCF7 (EGFR+) (Supplementary Fig. 1), 
which was concordant with the flow cytometry data using ZEGFR:03115-Dylight633 (Fig. 
1A).  
To demonstrate that ZEGFR:03115 specifically targets EGFR, HN5 cells were 
incubated with ZEGFR:03115-Dylight633 and the cell-associated fluorescence was 
visualized by confocal microscopy. After a 1 h incubation at 37°C, intense fluorescent 
signal was found on the cell membrane (Fig. 1B). Images acquired 3, 8 and 24 h later 
showed an intracellular accumulation of the conjugate, although the vast majority still 
remained bound to the membrane, even 24 h post-incubation (Fig. 1C). Additionally, 
incubating the cells with 100-fold excess of unlabeled ZEGFR:03115 markedly decreased 
the fluorescence signal (Fig. 1B bottom panel) demonstrating that binding is EGFR 
specific and receptor-mediated. 
 
In vitro Binding of 89Zr-DFO-ZEGFR:03115 
The disassociation constant (Kd) and maximum number of binding sites (Bmax) of 
89Zr-DFO-ZEGFR:03115 were determined by a cell-based saturation assay using CAL27 
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cells. The calculated Kd and Bmax values were found to be 5.00 ± 0.3 nM and (3.71 ± 
0.05)×106 sites/cell, respectively (Fig. 2A). The target-binding specificity of 89Zr-DFO-
ZEGFR:03115 was evaluated in a panel of cancer cell lines with different EGFR expression, 
demonstrating the cell-associated radioactivity was consistent with the measured total 
EGFR protein expression level in each cell line (Fig. 2B and Fig. 1A). Importantly, 
blocking the receptor with 100-fold excess of non-labeled ZEGFR:03115, cetuximab or the 
natural ligand EGF, which were demonstrated to compete with the Affibody molecule for 
the same binding site, significantly reduced radioactivity signal, further confirming the 
specificity of 89Zr-DFO-ZEGFR:03115 for the target (Fig. 2B).  
 
Protein Dose-Escalation Studies 
Protein dose-escalation studies were initially performed to test the bioavailability 
of the radioconjugate for tumor targeting. By adding increasing amounts of non-labeled 
Affibody molecule (1, 5, 10, 15, 20 µg) to the 89Zr-DFO-ZEGFR:03115 (2 µg, 2.5-3.4 
MBq/mouse), the radioactivity signal in the liver significantly decreased from 20.74 ± 
8.31 to 3.19 ± 0.14 %ID/g (Table 1). Concurrently, tumor uptake increased from 1.75 ± 
0.21 to 3.69 ± 1.19 %ID/g (Table 1, Fig. 3). Importantly, an insignificant uptake was 
achieved when the non-specific Affibody-based radioconjugate (89Zr-DFO-ZTaq) was 
injected in CAL27 tumors (0.26 ±0.05 %ID/g) (Table 1, Supplementary Fig. B2). Also, 
no significant differences in tumor uptake (3.69 ± 1.19 %ID/g vs 3.88 ± 0.46 %ID/g) 
were found when non-labeled ZEGFR:03115 was either injected 30 min before the 
radioconjugate or co-injected with the 89Zr-DFO-ZEGFR:03115 (Supplementary Fig. 2). 
Therefore, the protein dose of 10 µg was administered alongside the radioconjugate for 
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further studies, as it provided the best contrast between targeted and non-targeted 
tissues (tumor-to-background ratio of 10.25 at 3 h post-injection). 
 
89Zr-DFO-ZEGFR:03115 Pharmacokinetics 
The pharmacokinetics of the 89Zr-DFO-ZEGFR:03115 were evaluated by performing 
biodistribution studies at 3, 24 and 48 h post-injection of 2 µg (2.5-3.4 MBq) of 
radioconjugate with 10 µg of ZEGFR:03115. The tumor/muscle (T/M) and tumor/blood (T/B) 
ratios at 3 h were 10.31 and 1.04, respectively. Due to clearance from non-specific 
organs, both values increased at 24 h and 48 h post-injection with T/M of 17.35 and 
13.56 and T/B of 2.79 and 9.34, respectively (Table 2). At the same time, tumor uptake 
decreased from 3.88 ± 0.46 %ID/g at 3 h to 2.43 ± 0.27 %ID/g and 2.13 ± 0.12 %ID/g at 
24 and 48 h, respectively. As the higher tumor uptake would allow for better 
differentiation between the xenograft tumor types we therefore decided to perform the 
proceeding studies at 3 h post-injection. As expected, the kidney uptake remained 
relatively high over time (104.85 ± 11.10 %ID/g even after 48 h) as a result of 
glomerular filtration of the Affibody molecule followed by reabsorption, degradation and 
retention in proximal tubular cells. Additionally, as expected when using 89Zr-labeled 
agents radioactivity accumulation in the bone at 24 h (2.28 ± 0.27 %ID/g) and 48 h (3.44 
± 0.59 %ID/g), was detected.  
 
Correlation of 89Zr-DFO-ZEGFR:03115 Tumor Uptake and EGFR Expression 
To evaluate whether 89Zr-DFO-ZEGFR:03115 could distinguish between tumors with 
varying EGFR expression levels, mice bearing CAL27, Detroit562 and MCF7 xenografts 
received the radiotracer (2 µg co-injected with 10 µg of ZEGFR:03115; 2.4-3.4 MBq/mouse) 
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and were imaged 3 h post-injection using PET/CT. The quantified PET imaging data 
indicated that the highest levels of radioconjugate accumulation were in CAL27 tumors 
(4.73 ± 0.90 %ID/g), (Fig. 4A and Fig. 4B). Importantly, in vivo specificity of ZEGFR:03115 
was confirmed by the lower 89Zr-DFO-ZEGFR:03115 uptake in low EGFR expressing MCF7 
xenografts (1.41 ± 0.20 %ID/g). These data were then corroborated by the 
corresponding biodistribution results (Fig. 4B). Furthermore, tumor targeting by the 
radioconjugate correlated with EGFR expression measured ex vivo by Western blot 
analysis and immunohistochemical staining (Fig. 4C Top, Supplementary Fig. 3). In 
addition, the autoradiography of tissue slices from CAL27 and Detroit562 tumors 
confirmed marked differences in 89Zr-DFO-ZEGFR:03115 uptake as compared to MCF7 
tumors (Fig. 4C Bottom).  
 
Monitoring Cetuximab-Induced in vivo EGFR Downregulation  
To monitor the response to cetuximab treatment, the long-lived isotope, 
zirconium-89 (T1/2 = 78.4 h), was replaced with fluorine-18 (T1/2 = 108 min). In vitro 
characterization of 18F-AlF-NOTA-ZEGFR:03115 confirmed the high affinity (Kd = 5.4 ± 1.1 
nM) and specificity of the radioconjugate for EGFR (Supplementary Fig. 4). Following 
18F-AlF-NOTA-ZEGFR:03115 intravenous administration into mice bearing HN5 tumors, a 
significantly lower tumor uptake was observed in cetuximab-treated mice in comparison 
to control HN5 tumors, as shown both by the PET image quantification (6.29 ± 0.89 
%ID/g vs 2.37 ± 0.31 %ID/g) and the biodistribution data (6.18 ± 0.38 %ID/g vs 0.80 ± 
0.17 %ID/g) (Fig. 5; Supplementary Fig. 5A). PET quantification of the cetuximab-
treated mice yielded a slightly higher %ID/g than the biodistribution studies, which is 
likely due to the relatively high radioactivity in the blood at 1 h post-injection 
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(Supplementary Fig. 5B and 5C). However, when background subtraction was applied, 
only a small amount of the activity was present in the treated tumors (0.28 ± 0.26% ID/g) 
(Supplementary Fig. 5D). This significant decrease in the radioconjugate accumulation 
correlated with a downregulation of EGFR expression following cetuximab treatment as 
assessed by Western blot (r = 0.961, P < 0.0001) (Fig. 6A and B, Supplementary Fig. 
5E and 5F). Furthermore, discernible differences in phosphorylated EGFR and AKT 
were observed between control and treated mice (Fig. 6A). Additionally, a cetuximab-
induced decrease in EGFR expression was confirmed by the immunohistochemistry 
(Fig. 6C). No significant change in tumor uptake was measured when a group of mice 
were injected with 18F-AlF-NOTA-ZEGFR:03115 and a quantity of cetuximab which was 
estimated to be still circulating in the blood 13 days post-treatment (Supplementary Fig. 
B5F). This confirmed that the decrease in tumor uptake was not due to the mAb 
competing for the same epitope on the receptor. Additionally, no significant decrease in 
tumor uptake was measured (Supplementary Fig. 5G). 
 
DISCUSSION 
Despite evidence demonstrating an important prognostic role for EGFR in 
HNSCC, receptor expression is not predictive of response to EGFR-targeted therapy. 
This is potentially due to EGFR expression being evaluated in the major clinical trials by 
an immunohistochemistry-based scoring system, which may not reflect the 
heterogeneous receptor expression of the whole tumor mass and associated regional 
lymph node metastases. The integration of molecular imaging biomarkers into standard 
clinical protocols could address these limitations, providing a global representation of 
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tumor target expression and accessibility, enabling for image-guided selection of 
patients for EGFR-targeted therapies.  
Recently, therapeutic mAbs targeting EGFR have been radiolabeled with multiple 
radioisotopes to provide information about tumor targeting, pharmacokinetics and 
accumulation in critical normal organs (23-25). Even et al. reported that 89Zr-cetuximab-
PET shows large inter-patient variability in locally advanced head and neck squamous 
cell carcinomas and provides additional information about the accessibility of the drug 
into the tumor when compared with 18F-FDG-PET and EGFR expression evaluated by 
ex vivo methods (26). However, Niu et al. have demonstrated in different HNSCC 
xenografts that poor 64Cu-DOTA-panitumumab delivery may result in the lack of 
correlation between PET quantification and the EGFR protein expression (27).  
We, therefore, utilized a low molecular weight targeting vector (i.e. Affibody 
molecule), as the rapid extravasation from the blood vessels and enhanced tumor mass 
penetration, would provide favorable pharmacokinetics for imaging applications and 
facilitate the visualization of tumor regions inaccessible for mAb, particularly at early 
time points. In fact, van Dijk et al. have recently shown high and specific uptake of 111In-
cetuximab-F(ab’)2 as early as 4 h post-injection, with high imaging contrast at 24 h in 
FaDu xenografts. The authors additionally reported that the radioconjugate can monitor 
the effects of EGFR inhibition combined with irradiation in head and neck carcinoma 
models (23,28). However, EGFR targeting mAb fragments do not bind to murine EGFR, 
which limits the proper evaluation of the real tumor-to-background signal of these 
agents in preclinical models. To address this limitation, several recent studies, have 
investigated whether EGFR-specific Affibody molecules, which cross-react with EGFR 
of mouse origin, can delineate EGFR+ve tumors and provide high-contrast tumor 
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imaging in the presence of endogenous background levels of EGFR (15-17). In our 
study, we investigated the binding of ZEGFR:03115 in a panel of HNSCC models. The in 
vitro data clearly demonstrated that the fluorescent (ZEGFR:03115-Dylight633) and radio-
labeled (89Zr-DFO-ZEGFR:03115, 18F-AlF-NOTA-ZEGFR:03115) Affibody-based conjugates 
maintained a high binding affinity for EGFR and enabled the detection of differences in 
EGFR expression. The specificity for EGFR binding was confirmed by blocking assays 
with cetuximab and the natural ligand, EGF. To study the pharmacokinetics of 
ZEGFR:03115 at later time points we radiolabeled the Affibody molecule with a long lived 
PET radioisotope (17). A 89Zr was seen as a better-suited radionuclide than 124I for such 
studies since radiometals are retained more readily in cells than radiohalogens.  
Numerous studies have highlighted the importance of optimizing the protein dose 
when targeting EGFR in order to partially saturate endogenous EGFR expression in the 
liver and, subsequently, increase the tumor uptake (29,30). Therefore, we performed a 
protein dose-escalation study and found we can clearly visualize the tumor 3 h post co-
injecting 10 µg of ZEGFR:03115 alongside 89Zr-DFO-ZEGFR:03115 (T/M ratio of 10.31). 
Furthermore, radioconjugate tumor accumulation was confirmed to be EGFR specific, 
as PET imaging of MCF-7 (EGFR+) showed much lower accumulation of the 
radioconjugate than tumors with higher receptor expression. Moreover, the 89Zr-DFO-
ZTaq-related radioactivity in the CAL27 tumor (EGFR++++) was negligible. Importantly, 
the accumulation of 89Zr-DFO-ZEGFR:03115 in the tumor correlated with EGFR protein 
expression level, assessed ex vivo by tumor tissue lysates and EGFR staining of tumor 
sections derived from xenograft models with various levels of receptor expression. Our 
results successfully demonstrated the advantage of performing imaging at later time 
points with the Affibody molecule, as exemplified by the increase in tumor-to-
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background ratios. However, the decrease in tumor accumulation following the 3 h post-
injection would limit the sensitivity for discerning subtle changes in EGFR expression. 
Therefore, the 3 h time point was selected to compare the receptor levels between the 
xenograft models. Furthermore, the clinical use of an Affibody conjugate radiolabeled 
with 18F would be more suitable than 89Zr, due to a lower radiation exposure burden to 
the patient, a more desirable positron branching ratio and a shorter radioactive half-life 
(T1/2 = 108 min vs 78.4 h). We postulated that 18F-AlF-NOTA-ZEGFR:03115 could measure 
dynamic changes in receptor expression in response to EGFR inhibition. 
This may provide useful information for adaptive treatment schedules with anti-
EGFR mAbs, since current dosing of cetuximab is based on the patient’s weight and the 
only confirmed clinical variable that predicts response to this agent is the grade of skin 
toxicity that occurs after treatment initiation (31,32). Notably, following cetuximab 
treatment, we observed a significantly lower radioconjugate uptake in the group of mice 
treated with this mAb. Moreover, this change was in line with decreased EGFR protein 
levels evaluated by Western blot and immunohistochemistry. These results, together 
with the fact that no significant change in tumor volume was observed during the 
treatment, highlight the potential for utilizing EGFR imaging as a tool for assessing 
cetuximab efficacy based on the receptor level rather than purely relying on anatomical 
imaging. Of note, EGFR downregulation, due to the internalization and subsequent 
degradation of EGFR in lysosomes, has recently been reported to be an important 
determinant of the efficacy of cetuximab treatment for colorectal cancer (33). Our data 
suggest that it may be possible to evaluate this effect non-invasively using PET-based 
imaging with radiolabeled Affibody molecule. 
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Furthermore, immunostaining of tumor sections revealed the presence of 
residual EGFR positive cells that directly reflected their viability following cetuximab 
treatment. These results were corroborated by incomplete inhibition of pAKT signaling. 
The surviving cell populations were likely inaccessible for the bulky antibody, but 
potentially may have evaded cetuximab treatment by activating compensatory signaling 
pathways. However, we recognize that further investigations are needed to verify these 
findings, which may point the way to further treatment options for such tumors. In the 
future 18F-AlF-NOTA-ZEGFR:03115 could also be utilized for the identification of residual 
EGFR-positive cells that may be responsible for subsequent cancer relapse.  
 
In summary, our results demonstrate that non-invasive molecular imaging of 
EGFR may open the door for guiding selection and monitoring of anti-EGFR targeted 
therapy dosing plans before tumor response, as measured by changes in tumor 
volumes on conventional cross-sectional imaging modalities, is detected. Such an 
approach may spare patients unnecessary toxicities and improve EGFR-targeted 
therapy by tailoring a more personalized treatment.  
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Figure 1: EGFR expression as determined by flow cytometry in the selected cancer cell 
lines (A). In vitro binding specificity of ZEGFR:03115-Dylight633 in HN5 cells as shown by 
confocal microscopy (B). Internalization studies of ZEGFR:03115-Dylight633 3 h, 8 h and 24 
h post 1 h incubation in HN5 cells (C).  
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Figure 2: Saturation curve obtained for CAL27 cells incubated with increasing 
concentrations of 89Zr-DFO-ZEGFR:03115  (A). In vitro binding specificity of 89Zr-DFO-
ZEGFR:03115 in the selected cell lines with and without blocking using unlabeled Affibody, 
cetuximab or EGF. Data are normalized to the maximum cell-associated radioactivity 
per experiment (B).  
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Figure 3: Whole-body coronal PET/CT images acquired 3 h after 89Zr-DFO-ZEGFR:03115 
administration spiked with different amounts of non-labeled ZEGFR:03115 in mice bearing 
CAL27 tumors: I) 2 µg of 89Zr-DFO-ZEGFR:03115 administered; II) 1 µg of ZEGFR:03115 
injected 30 mins prior to injection of 2 µg of 89Zr-DFO-ZEGFR:03115; III) 5 µg of ZEGFR:03115 
injected 30 mins prior to injection of 2 µg of 89Zr-DFO-ZEGFR:03115; IV) 10 µg of ZEGFR:03115 
injected 30 mins prior to injection of 2 µg of 89Zr-DFO-ZEGFR:03115; V) 10 µg of ZEGFR:03115 
co-injected with 2 µg of 89Zr-DFO-ZEGFR:03115. 
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Figure 4: Radioconjugate uptake in xenografts with varying EGFR expression. 
Representative whole-body sagittal fused PET/CT images acquired 3 h after injection 
(A). PET quantification of radiotracer uptake in tumors (outlined on the image) 3 h after 
injection in comparison with data obtained from the biodistribution studies. Data are 
presented as mean ± SD (****P < 0.0001, ***P < 0.001, **P < 0.01) (B). 
Histopathological analysis of EGFR expression in the xenograft models (CTop). 
Representative autoradiography tumor sections 3 h post radioconjugate administration 
(CBottom).  
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Figure 5: 18F-AlF-NOTA-ZEGFR:03115 uptake assessed 1 h post-injection. Representative 
sagittal whole-body fused PET/CT images of mice bearing HN5 tumors (outlined on the 
image) with or without treatment with cetuximab (A). PET quantification in control and 
cetuximab treated HN5 tumors and corresponding biodistribution %ID/g values (B). 
Data are reported as mean ± SD (n ≥ 6); (****P < 0.0001). 
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Figure 6: Western blot of tumor tissue lysates from control and cetuximab treated mice 
demonstrating EGFR protein expression, activation and downstream signaling (A). 
Spearman’s rank correlation analysis for EGFR expression as determined by Western 
blot against 18F-AlF-NOTA-ZEGFR:03115 tumor uptake as quantified by PET image 
analysis. The dashed lines represent the 95% confidence levels (B). Histopathological 
analysis of EGFR expression and H&E staining in HN5 xenografts in both a control and 
cetuximab treated mouse (C). 
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Organ 
 (%ID/g) 
2 µg  
89Zr-DFO-ZEGFR:03115 2µg   89Zr-DFO-ZTaq 
0 µg   
ZEGFR:03115  1 µg   ZEGFR:03115  5 µg   ZEGFR:03115 10 µg   ZEGFR:03115  20 µg  ZEGFR:03115 10µg   ZEGFR:03115  
Blood 3.52±1.42 6.01±0.18 3.87±0.30 4.46±1.65 3.06±0.20 0.64±0.04 
Heart 0.89±0.22 1.53±0.05 0.95±0.09 1.03±0.29 0.77±0.06 0.25±0.03 
Lungs 1.45±0.45 2.55±0.23 1.84±0.50 2.05±0.1.06 1.45±0.08 0.47±0.05 
Kidney 37.14±1.17 54.52±17.13 73.26±12.91 140.84±47.70 109.14±22.30 172.04±20.07 
Spleen 0.91±0.10 1.58±0.23 0.94±0.20 1.28±0.13 0.94±0.13 0.37±0.08 
Liver 20.74±8.31 10.36±1.49 3.82±0.39 4.25±1.55 3.19±0.14 0.82±0.22 
Pancreas 0.73±0.19 1.62±0.24 0.71±0.12 0.69±0.13 0.46±0.04 0.14±0.03 
Tumor 1.75±0.21 1.70±0.68 1.87±0.58 3.69±1.19 2.59±0.48 0.26±0.05 
Bone 1.35±0.24 1.24±0.21 0.81±0.15 0.87±0.14 0.66±0.09 0.21±0.05 
Intestine 0.59±0.28 1.62±0.57 0.90±0.11 0.89±0.11 0.81±0.05 0.19±0.03 
Muscle 0.24±0.01 0.35±0.07 0.37±0.09 0.36±0.05 0.33±0.04 0.08±0.03 
Tumor/Blood 0.50 0.28 0.48 0.83 0.85 0.41 
Tumor/Muscle 7.29 4.86 5.05 10.25 7.85 3.15 
Tumor/Liver  0.08 0.16 0.49 0.87 0.81 0.32 
 
Table 1: Biodistribution results 3 h post-administration of increasing amounts of non-
labeled ZEGFR:03115 30 mins prior to 2 µg 89Zr-DFO-ZEGFR:03115 or 2 µg 89Zr-DFO-ZTaq in 
CAL27 xenografts. Data are reported as mean ± SD (n ≥ 3) of injected dose per gram of 
tissue. 
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Organ (%ID/g) 3 h 24 h 48 h 
Blood 3.70±0.55 0.87±0.32 0.23±0.06 
Heart 0.99±0.19 0.37±0.12 0.31±0.04 
Lungs 2.74±0.93 0.88±0.13 0.70±0.08 
Kidney 130.42±22.25 108.80±19.60 104.85±11.10 
Spleen 1.14±0.18 0.72±0.20 0.79±0.37 
Liver 4.99±0.85 4.31±1.00 4.11±1.41 
Pancreas 0.67±0.14 0.36±0.10 0.35±0.25 
Tumor 3.88±0.46 2.43±0.27 2.13±0.12 
Bone 0.99±0.28 2.28±0.27 3.44±0.59 
Intestine 1.09±0.16 0.42±0.03 0.40±0.02 
Muscle 0.38±0.09 0.14±0.04 0.16±0.07 
Tumor/Blood 1.04 2.79 9.34 
Tumor/Muscle 10.31 17.35 13.56 
Tumor/Liver 0.78 0.56 0.52 
 
Table 2: Ex vivo biodistribution results 3, 24 and 48 h post 89Zr-DFO-ZEGFR:03115 
injection. Data are reported as mean ± SD (n ≥ 3) of injected dose per gram of tissue 
following the intravenous injection of 2 µg 89Zr-DFO-ZEGFR:03115 co-injected with 10 µg 
non-labeled ZEGFR:03115 in mice bearing CAL27 xenografts. 
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